Matches in SemOpenAlex for { <https://semopenalex.org/work/W3170142010> ?p ?o ?g. }
- W3170142010 endingPage "943" @default.
- W3170142010 startingPage "943" @default.
- W3170142010 abstract ": Glioblastoma multiforme (GBM) is the most aggressive, common, and lethal subtype of malignant gliomas originating from the central nervous system. Currently, the standard therapy for GBM is surgical resection combined with radiation and temozolomide (TMZ). However, the treatment only improves the 2-year survival rate from 10% to 26%, accompanied by more than 90% recurrence of GBM tumors at the original site. Low survival rate, serious side effects, and poor prognosis force people to find new therapies. Recent years, the combination of clinical drugs improves the survival rate of GBM patients, but new therapeutic drugs with high-efficiency and low-toxicity are still needed to be discovered. The successful use of immunotherapy in tumor brings hope for people to explore new methods in treating GBM. While the inability to cross the blood-brain barrier (BBB), loss of lymphatic tissue drainage, and antigen-presenting cells in the central nervous system are major reasons for the failure of immunotherapy in the treatment of GBM. Glioma stem cells (GSCs) is a subtype of tumorigenic stem cells which has more specific tumorigenic potential indicating targeting GSCs may be expected to improve therapeutic efficacy. In this review, we discuss clinical drugs that have benefited patients with GBM, cancer immunotherapy for GBM, summarize new drug targets of GBM, and review strategies for increasing the passage of drugs through the BBB." @default.
- W3170142010 created "2021-06-22" @default.
- W3170142010 creator A5000994133 @default.
- W3170142010 creator A5001941855 @default.
- W3170142010 creator A5008743951 @default.
- W3170142010 creator A5014353611 @default.
- W3170142010 creator A5033681865 @default.
- W3170142010 creator A5080080275 @default.
- W3170142010 creator A5081491208 @default.
- W3170142010 creator A5082032813 @default.
- W3170142010 date "2021-06-01" @default.
- W3170142010 modified "2023-09-25" @default.
- W3170142010 title "A narrative review of research progress on drug therapies for glioblastoma multiforme" @default.
- W3170142010 cites W111616551 @default.
- W3170142010 cites W1828443506 @default.
- W3170142010 cites W1896894019 @default.
- W3170142010 cites W1964113455 @default.
- W3170142010 cites W1966743152 @default.
- W3170142010 cites W1978041336 @default.
- W3170142010 cites W1981560408 @default.
- W3170142010 cites W1982236564 @default.
- W3170142010 cites W1983852551 @default.
- W3170142010 cites W1988299559 @default.
- W3170142010 cites W1988756388 @default.
- W3170142010 cites W1995037165 @default.
- W3170142010 cites W1996719014 @default.
- W3170142010 cites W2009914447 @default.
- W3170142010 cites W2016760158 @default.
- W3170142010 cites W2024672608 @default.
- W3170142010 cites W2025515800 @default.
- W3170142010 cites W2030718440 @default.
- W3170142010 cites W2032644486 @default.
- W3170142010 cites W2043451385 @default.
- W3170142010 cites W2053619773 @default.
- W3170142010 cites W2064341586 @default.
- W3170142010 cites W2078791896 @default.
- W3170142010 cites W2079095609 @default.
- W3170142010 cites W2079203845 @default.
- W3170142010 cites W2083081144 @default.
- W3170142010 cites W2087532530 @default.
- W3170142010 cites W2093783077 @default.
- W3170142010 cites W2096287682 @default.
- W3170142010 cites W2096800614 @default.
- W3170142010 cites W2101037339 @default.
- W3170142010 cites W2101099825 @default.
- W3170142010 cites W2101129009 @default.
- W3170142010 cites W2105879190 @default.
- W3170142010 cites W2111485768 @default.
- W3170142010 cites W2114147900 @default.
- W3170142010 cites W2116485123 @default.
- W3170142010 cites W2116991471 @default.
- W3170142010 cites W2119793842 @default.
- W3170142010 cites W2121585125 @default.
- W3170142010 cites W2123610802 @default.
- W3170142010 cites W2124736921 @default.
- W3170142010 cites W2127667670 @default.
- W3170142010 cites W2128469603 @default.
- W3170142010 cites W2140308968 @default.
- W3170142010 cites W2148977460 @default.
- W3170142010 cites W2151335185 @default.
- W3170142010 cites W2158649478 @default.
- W3170142010 cites W2165772224 @default.
- W3170142010 cites W2165917993 @default.
- W3170142010 cites W2166356961 @default.
- W3170142010 cites W2167713837 @default.
- W3170142010 cites W2167923186 @default.
- W3170142010 cites W2169798272 @default.
- W3170142010 cites W2171714209 @default.
- W3170142010 cites W2190350005 @default.
- W3170142010 cites W2193600641 @default.
- W3170142010 cites W2205491921 @default.
- W3170142010 cites W2270804882 @default.
- W3170142010 cites W2292758320 @default.
- W3170142010 cites W2336724059 @default.
- W3170142010 cites W2417156925 @default.
- W3170142010 cites W2433010802 @default.
- W3170142010 cites W2465806199 @default.
- W3170142010 cites W2488777145 @default.
- W3170142010 cites W2515247601 @default.
- W3170142010 cites W2527734859 @default.
- W3170142010 cites W2555156914 @default.
- W3170142010 cites W2567424265 @default.
- W3170142010 cites W2600626962 @default.
- W3170142010 cites W2604638977 @default.
- W3170142010 cites W2604973399 @default.
- W3170142010 cites W2746246740 @default.
- W3170142010 cites W2749747068 @default.
- W3170142010 cites W2761941966 @default.
- W3170142010 cites W2765824670 @default.
- W3170142010 cites W2768388636 @default.
- W3170142010 cites W2769373441 @default.
- W3170142010 doi "https://doi.org/10.21037/atm-20-8017" @default.
- W3170142010 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8263870" @default.
- W3170142010 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34350258" @default.
- W3170142010 hasPublicationYear "2021" @default.
- W3170142010 type Work @default.
- W3170142010 sameAs 3170142010 @default.
- W3170142010 citedByCount "7" @default.